Medical Oncology Division, Ente Ospedaliero Ospedali Galliera
Welcome,         Profile    Billing    Logout  
 8 Trials 
15 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
DeCensi, Andrea
NCT04460807: Exemestane in Hormone Receptor Positive High Grade Ovarian Cancer

Terminated
3
23
Europe
Exemestane, Mestane, Placebo oral tablet
Ente Ospedaliero Ospedali Galliera, Istituto Di Ricerche Farmacologiche Mario Negri, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Federation of Italian Cooperative Oncology Groups
Ovarian Cancer
04/23
04/23
TAM-01, NCT01357772 / 2007-007740-10: Trial of Low Dose Tamoxifen in Women With Breast Intraepithelial Neoplasia - Long Term Follow-up

Active, not recruiting
3
500
Europe
Tamoxifen, Tamoxifen citrate (ATC code: L02BA01), placebo
Andrea DeCensi, Associazione Italiana per la Ricerca sul Cancro, European Institute of Oncology
Carcinoma, Intraductal, Noninfiltrating, Recurrence, Local Neoplasm, Breast Neoplasms, Atypical Hyperplasia
12/22
12/28
LEPRE, NCT05601700 / 2020-003066-39: Letrozole for Estrogen/Progesterone Receptor Positive Low-grade Serous Epithelial Ovarian Cancer ( Trial)

Recruiting
3
132
Europe
Letrozole tablets, carboplatin AUC 5 and paclitaxel 175 mg/m2
Ente Ospedaliero Ospedali Galliera, Istituto Di Ricerche Farmacologiche Mario Negri, Humanitas Hospital, Italy
Carcinoma, Ovarian Epithelial, Low Grade Serous Adenocarcinoma of Ovary
09/29
09/29
TOLERANT, NCT06033092: Low Dose TamOxifen and LifestylE Changes for bReast cANcer prevenTion

Not yet recruiting
2
200
Europe
Tamoxifen 10 mg Tablet, Low dose tamoxifen, Intermittent caloric restriction, Step counter Device
European Institute of Oncology, Ente Ospedaliero Ospedali Galliera, Istituto Oncologico Veneto IRCCS, Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale
BRCA Mutation, PALB2 Gene Mutation, Ductal Carcinoma in Situ, Lobular Carcinoma in Situ, ATM Gene Mutation, CHEK2 Gene Mutation, CDH1 Gene Mutation, RAD51C Gene Mutation, RAD51D Gene Mutation
07/25
07/26
Censi, Andrea De
CANAL, NCT05725343: A Prevention Trial of Canakinumab in Subjects at High Risk for Lung Cancer

Terminated
3
350
Europe
Canakinumab, ilaris, Placebo
Mario Negri Institute for Pharmacological Research, Novartis Pharmaceuticals
Lung Cancer
04/22
09/22
NCT04460807: Exemestane in Hormone Receptor Positive High Grade Ovarian Cancer

Terminated
3
23
Europe
Exemestane, Mestane, Placebo oral tablet
Ente Ospedaliero Ospedali Galliera, Istituto Di Ricerche Farmacologiche Mario Negri, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Federation of Italian Cooperative Oncology Groups
Ovarian Cancer
04/23
04/23
LEPRE, NCT05601700 / 2020-003066-39: Letrozole for Estrogen/Progesterone Receptor Positive Low-grade Serous Epithelial Ovarian Cancer ( Trial)

Recruiting
3
132
Europe
Letrozole tablets, carboplatin AUC 5 and paclitaxel 175 mg/m2
Ente Ospedaliero Ospedali Galliera, Istituto Di Ricerche Farmacologiche Mario Negri, Humanitas Hospital, Italy
Carcinoma, Ovarian Epithelial, Low Grade Serous Adenocarcinoma of Ovary
09/29
09/29
ASAMET, NCT03047837 / 2015-004824-77: A Randomized, 2x2 Factorial Design Biomarker Prevention Trial of Low-dose ASA and Metformin in Stage I-III Crc Patients

Active, not recruiting
2
160
Europe
ASA, Cardioaspirin, MET, Metformin, Placebo
Ente Ospedaliero Ospedali Galliera
Tertiary Prevention in Colon Cancer
03/24
03/24
BabyTears, NCT06364267: Low Dose Tamoxifen vs Low Dose Exemestane in Post-menopausal Women at High Risk for Breast Cancer.

Not yet recruiting
2
160
Europe
Tamoxifen 10 MG, Exemestane 25 MG
Andrea DeCensi, Dana-Farber/Brigham and Women's Cancer Center, Herbert Irving Comprehensive Cancer Center, Istituto Europeo di Oncologia, Breast Cancer Research Foundation
Breast Cancer
09/26
09/26
ROME, NCT04591431 / 2018-002190-21: The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy

Active, not recruiting
2
400
Europe
Erlotinib, Trastuzumab, Trastuzumab emtansine, Pertuzumab, Lapatinib, Everolimus, Vemurafenib, Cobimetinib, Alectinib, Brigatinib, Palbociclib, Ponatinib, Vismogedib, Itacitinib, Ipatasertib, Entrectinib, Atezolizumab, Nivolumab, Ipilimumab, Pemigatinib, Oncology Drugs, Pralsetinib, Selpercatinib, Talazoparib, Tepotinib, Alpelisib
Fondazione per la Medicina Personalizzata
Breast Cancer, Gastrointestinal Cancer, Non Small Cell Lung Cancer, Other Cancer
12/24
06/25
NCT05023967: Metformin and Nightly Fasting in Women With Early Breast Cancer

Recruiting
2
120
Europe, US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Extended Release Metformin Hydrochloride, ER Metformin Hydrochloride, Extended-release Metformin Hydrochloride, Glucophage XR, Glumetza, Metformin Hydrochloride Extended Release, Monitoring, monitor, Nutritional Assessment, Dietary Assessment, dietary counseling, nutritional counseling, Short-Term Fasting, Intermittent Fasting, Short-term Intermittent Fasting
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Breast Ductal Carcinoma In Situ, Invasive Breast Carcinoma
11/25
11/25
NCT05122052: Effect of Gender on Distress and Fatigue in Cancer Patients

Recruiting
N/A
500
Europe
Psychological session
Ente Ospedaliero Ospedali Galliera
Cancer
09/24
03/25
UNICO, NCT04932863: BNT162b2 Messenger Ribonucleic Acid (mRNA) Covid-19 Vaccine in Cancer Patients on Active Treatment

Recruiting
N/A
300
Europe
BNT162b2 mRNA Covid-19 Vaccine
Ente Ospedaliero Ospedali Galliera, University of Genoa
Neoplasms, Cancer, Treatment-Related
03/22
03/23
Provinciali, Nicoletta
NCT04460807: Exemestane in Hormone Receptor Positive High Grade Ovarian Cancer

Terminated
3
23
Europe
Exemestane, Mestane, Placebo oral tablet
Ente Ospedaliero Ospedali Galliera, Istituto Di Ricerche Farmacologiche Mario Negri, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Federation of Italian Cooperative Oncology Groups
Ovarian Cancer
04/23
04/23
LEPRE, NCT05601700 / 2020-003066-39: Letrozole for Estrogen/Progesterone Receptor Positive Low-grade Serous Epithelial Ovarian Cancer ( Trial)

Recruiting
3
132
Europe
Letrozole tablets, carboplatin AUC 5 and paclitaxel 175 mg/m2
Ente Ospedaliero Ospedali Galliera, Istituto Di Ricerche Farmacologiche Mario Negri, Humanitas Hospital, Italy
Carcinoma, Ovarian Epithelial, Low Grade Serous Adenocarcinoma of Ovary
09/29
09/29

Download Options